Mereo BioPharma(US:MREO) Globenewswire·2026-03-08 05:25Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs between June 5, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with misleading information regarding the expected results of its Phase 3 clinical studies for setrusumab in treating Osteogenesis Imperfecta [5]. - Defendants allegedly made positive statements about the drug's potential while concealing adverse facts about the studies, which did not meet their primary endpoints [6]. - As a result of these misleading statements, investors purchased Mereo's ADSs at inflated prices, leading to financial damages when the true information was revealed [6].